Daewoong Pharmaceutical Indonesia

Daewoong Highlights Indonesian IIT Data at JIGES-LD x IDEN 2026, Strengthening Local GI Innovation

Writer

Manager

February 24, 2026

- Daewoong Pharmaceutical Indonesia reinforced its commitment to advancing gastrointestinal care by presenting locally generated clinical evidence at a national scientific forum attended by more than 351 doctors from across Indonesia.

- The highlight was the presentation of Indonesian Investigator-Initiated Trial (IIT) data by Prof. Dr. dr. Ari Fahrial Syam, Chairman of the Indonesian Society of Gastroenterology, underscoring the importance of locally based evidence in GERD management.

- The event strengthened nationwide engagement with healthcare professionals, reaffirming Daewoong’s more than 20-year role as a long-term growth partner equipping Indonesia with innovative, evidence-based therapies.

‍

Jakarta, February 25^th, 2026 — Daewoong Pharmaceutical Indonesia (DPI) participated in The First Jakarta International Gastrointestinal (GI) Endoscopy Symposium & Live Demonstration (JIGES-LD) held in conjunction with the International Digestive Endoscopy Network (IDEN) 2026, reaffirming its commitment to advancing GI care through locally generated clinical evidence and nationwide physician engagement.

‍

The symposium brought together more than 351 doctors and healthcare professionals from across Indonesia, including gastroenterologists and internal medicine specialists from multiple provinces, establishing a high-level scientific platform to discuss advancements in gastrointestinal disease management.

Prof. Dr. dr. Ari Fahrial Syam (3rd from left), Chairman of the Indonesian Society of Gastroenterology, and dr. Stella Melisa (2nd from right), Chief Medical Officer of Daewoong Pharmaceutical Indonesia, at the Daewoong booth during JIGES-LD x IDEN 2026, reflecting collaborative efforts to strengthen local clinical evidence and enhance GERD treatment standards in Indonesia.

‍

Indonesian Investigator-Initiated Trial (IIT) Data Presented by Chairman of the Indonesian Society of Gastroenterology

A central highlight of Daewoong’s participation was the half-symposium session delivered by Prof. Dr. dr. Ari Fahrial Syam, SpPD-KGEH, MMB, FINASIM, FACP, Chairman of the Indonesian Society of Gastroenterology. The session, titled “Emerging Evidence on Potassium-Competitive Acid Blockers: Insights from Indonesian Clinical Trial,” presented findings from Indonesia’s Investigator-Initiated Trial (IIT) evaluating Fexuprazan in Gastroesophageal Reflux Disease (GERD) patients.

‍

The Indonesian IIT was conducted across three leading hospitals in Jakarta namely Rumah Sakit Universitas Indonesia (RSUI), Rumah Sakit Islam (RSI) Cempaka Putih, Rumah Sakit Menteng Mitra Afia (RSMMA).

‍

The study involved 134 Indonesian GERD patients, generating locally relevant clinical evidence that reflects real-world patient characteristics and treatment response within the Indonesian healthcare setting.

‍

An Investigator-Initiated Trial (IIT) is a clinical study independently designed and led by physicians to address practical clinical questions encountered in daily medical practice. By involving patients treated in major referral centers in Jakarta, the study aimed to bridge the gap between global clinical data and local clinical needs.

‍

The trial compared Fexuprazan 40 mg with Esomeprazole 40 mg, demonstrating non-inferiority in efficacy, with advantages observed in faster symptom improvement and patient-reported outcomes, critical considerations in outpatient GERD management.

‍

Prof. Ari Fahrial Syam stated, “this Investigator-Initiated Trial involved 134 Indonesian GERD patients across RSUI, RSI Cempaka Putih, and RSMMA. The availability of locally generated data is essential to strengthen clinical confidence and support better GERD management tailored to Indonesian patients.”

Prof. Dr. dr. Ari Fahrial Syam, Chairman of the Indonesian Society of Gastroenterology, delivering his presentation on Indonesian Investigator-Initiated Trial (IIT) findings in Gastroesophageal Reflux Disease (GERD) during the Daewoong half-symposium at JIGES-LD x IDEN 2026.

‍

The availability of Indonesian-based clinical evidence directly addresses the demand among healthcare professionals for localized validation and supports evidence-based therapeutic decisions that may enhance patients’ quality of life.

‍

Nationwide Physician Engagement and Clinical Insights

Beyond the symposium session, DPI engaged physicians from Java, Sumatra, Kalimantan, Sulawesi, and other regions, reflecting broad national representation. More than 140 doctors visited Daewoong’s booth, and over 110 healthcare professionals participated in structured discussions and questionnaires, providing insights into current GERD management practices.

‍

Key themes identified include persistent incomplete symptom relief with standard therapy, the importance of rapid onset of action, adherence considerations, and access challenges outside major urban areas.

‍

dr. Stella Melisa, Chief Medical Officer of Daewoong Pharmaceutical Indonesia, commented, “direct engagement with doctors from across Indonesia enables us to understand real-world clinical challenges. These insights are essential to refine our medical education strategy and ensure innovation translates into meaningful benefits for Indonesian patients.”

The DPI medical team interacting with gastroenterologists and internal medicine specialists at JIGES-LD x IDEN 2026, facilitating evidence-based dialogue on innovative Gastrointestinal (GI) therapies for Indonesian patients.

‍

More Than 20 Years as Indonesia’s Growth Partner

For more than two decades, Daewoong has grown alongside Indonesia by investing in scientific collaboration, local capability development, and sustained engagement with healthcare professionals. The company remains committed to supporting locally based clinical research and equipping Indonesian clinicians with innovative therapies aligned with global standards.

Mr. Baik In Hyun (3rd from left), Director of Daewoong Pharmaceutical Indonesia, at JIGES-LD x IDEN 2026, reaffirming the company’s commitment to advancing locally based clinical evidence and strengthening gastrointestinal care standards in Indonesia.

‍

Mr. Baik In Hyun, Director of Daewoong Pharmaceutical Indonesia, stated, “Daewoong remains committed to supporting locally based clinical evidence and equipping Indonesian healthcare professionals with innovative therapies that enhance patients’ quality of life. Through sustained collaboration with the medical community, we aim to contribute meaningfully to advancing gastrointestinal care standards across Indonesia.”

‍

Daewoong Pharmaceutical Indonesia continues to focus on innovation grounded in science, supported by local evidence, and aligned with the evolving needs of patients throughout the archipelago.

list

- Daewoong Pharmaceutical Indonesia reinforced its commitment to advancing gastrointestinal care by presenting locally generated clinical evidence at a national scientific forum attended by more than 351 doctors from across Indonesia.

- The highlight was the presentation of Indonesian Investigator-Initiated Trial (IIT) data by Prof. Dr. dr. Ari Fahrial Syam, Chairman of the Indonesian Society of Gastroenterology, underscoring the importance of locally based evidence in GERD management.

- The event strengthened nationwide engagement with healthcare professionals, reaffirming Daewoong’s more than 20-year role as a long-term growth partner equipping Indonesia with innovative, evidence-based therapies.

Privacy Policy

이용약관